CANDEL THERAPEUTICS INC (CADL)
US1374041093 - Common Stock
Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
NEEDHAM, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused...
In today's session, these stocks are experiencing unusual volume.
The trading volume of these stocks is deviating from the norm in today's session.
Which stocks are moving on Friday?
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
These stocks have an unusual volume in today's session
These stocks have an unusual volume in today's session
Top movers in Friday's session
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.
Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Top movers in Friday's pre-market session
Discover the top movers in Friday's pre-market session and stay informed about market dynamics.
Candel Therapeutics Announces Pricing of Public Offering
Candel Therapeutics Announces Pricing of Public Offering
NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused...
Candel Therapeutics Announces $80 Million Proposed Public Offering
Candel Therapeutics Announces $80 Million Proposed Public Offering
NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused...
Which stocks are moving on Thursday?
Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session.
In today's session, these stocks are experiencing unusual volume.
Which stocks have an unusual volume on Thursday?
What's going on in today's session
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Wednesday's session: top gainers and losers
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
These stocks are the most active in today's session
Curious about the most active stocks in today's session? Get a glimpse into the stocks that are generating the highest trading volume and capturing market attention.
Which stocks are experiencing notable movement on Wednesday?
Which stocks are experiencing notable movement on Wednesday?
The market is filled with gapping stocks in Wednesday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Gap analysis on 2024-12-11: gap up and gap down stocks in today's session.
Candel Therapeutics Stock Surges Over 100% - Here's Why
On Wednesday, Candel Therapeutics, Inc. (NASDAQ:CADL) announced results from a phase 3 trial of CAN-2409 viral immunotherapy in intermediate-to-high-risk, localized prostate cancer patients. The trial met its primary endpoint and demonstrated statistically significant improvement in disease-free survival in patients who received CAN-2409 plus the prodrug (valacyclovir) combined with the standard of care compared to the standard of care alone. CAN-2409, when administered with valacyclovir, is des
Candel Skyrockets By Triple Digits On A Potential First-In-20-Years Cancer Drug
The company is hoping to eventually launch the first major new treatment for localized prostate cancer in over 20 years.
Top movers in Wednesday's pre-market session
Top movers in Wednesday's pre-market session
Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival
Positive topline data for CAN-2409 viral immunotherapy achieved primary endpoint by demonstrating statistically significant and clinically meaningful...
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
Candel Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
On track for topline disease-free survival data from the phase 3 randomized controlled clinical trial of CAN-2409 in localized intermediate/high risk...
Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024
Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma
Abstract selected as poster presentation during the Society for Immunotherapy of Cancer (SITC) Annual Meeting shows potent antitumor activity of CAN-3110...
Candel Therapeutics Becomes Oversold (CADL)
Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)
Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)
NEEDHAM, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced three presentations at the 16th Annual International Oncolytic Virotherapy Conference (IOVC), taking place October 27-30, 2024, in Rotterdam, the Netherlands.
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
NEEDHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical...
Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
CADL Stock Earnings: Candel Therapeutics Reported Results for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Candel Therapeutics (NASDAQ:CADL) just reported results for the second quarter ...
CADL Stock Earnings: Candel Therapeutics Reported Results for Q2 2024
Candel Therapeutics just reported results for the second quarter of 2024.
Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
Announced positive survival data from the phase 2 randomized controlled clinical trial of CAN-2409 in borderline resectable pancreatic cancerPresented...
Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates
/PRNewswire/ -- USA News Group – Pancreatic cancer is among the deadliest cancers, prompting researchers to focus on early detection to improve survival rates....